Despite the lack of efficacy as a monotherapy, three phase I/II studies are currently recruiting participants: one for AML in combination with decitabine or cytarabine (NCT03303339), one for metastatic prostate cancer in combination with FOLFIRI (folinic acid, fluorouracil, and irinotecan) and bevacizumab (NCT03829410), and one for metastatic colorectal cancer with a KRAS mutation in combination with abiraterone and prednisone (NCT03414034). The gene discussed is KRAS; the disease is metastatic prostate carcinoma.